Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioSyent Inc. (RX.V)
Mississauga, ON, CA
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.07% | -5.25% | -2.70% | -0.41% | +31.27% | +13.43% | +22.89% | +90.00% | +92.28% | +109.28% | +702.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+22.9% ★ Q1'26: +26.7% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+25.8% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+18.9% Q1'26: +21.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+26.3% ★ Q1'26: +22.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+62.1% ★ Q1'26: +23.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-2.6% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.07× ★ Q1'26: 0.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.39M
est: 15.20M (+1.2%)
|
17.92M
est: 17.24M (+3.9%)
|
20.76M
est: 20.70M (+0.3%)
|
21.53M
est: 21.76M (-1.1%)
|
21.42M
est: 21.50M (-0.4%)
|
22.33M
est: 22.05M (+1.3%)
|
28.62M
est: 28.10M (+1.8%)
|
27.93M
est: 27.40M (+1.9%)
|
31.59M
est: 32.10M (-1.6%)
|
35.03M
est: 35.40M (-1.0%)
|
43.05M
est: 43.60M (-1.3%)
|
68.60M
68.60M – 68.60M
+57.3% YoY
|
79.00M
79.00M – 79.00M
+15.2% YoY
|
83.60M
83.60M – 83.60M
+5.8% YoY
|
| EBITDA |
5.12M
est: 4.26M (+20.2%)
|
5.90M
est: 4.83M (+22.1%)
|
7.04M
est: 5.80M (+21.4%)
|
7.73M
est: 6.10M (+26.8%)
|
6.19M
est: 6.02M (+2.9%)
|
5.54M
est: 6.18M (-10.3%)
|
8.64M
est: 7.87M (+9.8%)
|
7.43M
est: 7.68M (-3.2%)
|
9.06M
est: 8.99M (+0.7%)
|
10.43M
est: 10.16M (+2.7%)
|
12.17M
est: 12.51M (-2.8%)
|
19.69M
19.69M – 19.69M
+57.3% YoY
|
22.68M
22.68M – 22.68M
+15.2% YoY
|
24.00M
24.00M – 24.00M
+5.8% YoY
|
| EBIT |
5.06M
est: 4.00M (+26.6%)
|
5.75M
est: 4.53M (+26.9%)
|
6.38M
est: 5.44M (+17.2%)
|
7.55M
est: 5.72M (+31.9%)
|
5.90M
est: 5.65M (+4.4%)
|
5.03M
est: 5.80M (-13.2%)
|
8.18M
est: 7.39M (+10.8%)
|
6.98M
est: 7.20M (-3.1%)
|
8.60M
est: 8.44M (+1.9%)
|
9.84M
est: 9.57M (+2.8%)
|
11.31M
est: 11.79M (-4.0%)
|
18.55M
18.55M – 18.55M
+57.3% YoY
|
21.36M
21.36M – 21.36M
+15.2% YoY
|
22.61M
22.61M – 22.61M
+5.8% YoY
|
| Net Income |
3.76M
est: 2.95M (+27.5%)
|
4.31M
est: 3.37M (+28.1%)
|
5.21M
est: 4.25M (+22.5%)
|
5.71M
est: 4.53M (+26.0%)
|
4.37M
est: 3.66M (+19.4%)
|
3.80M
est: 3.54M (+7.1%)
|
6.28M
est: 4.84M (+29.8%)
|
5.46M
est: 5.08M (+7.5%)
|
6.46M
est: 6.85M (-5.7%)
|
7.27M
est: 7.25M (+0.3%)
|
9.01M
est: 9.09M (-0.9%)
|
10.82M
10.82M – 10.82M
+19.0% YoY
|
12.89M
12.89M – 12.89M
+19.1% YoY
|
14.38M
14.38M – 14.38M
+11.6% YoY
|
| SGA |
7.03M
est: 7.88M (-10.8%)
|
8.31M
est: 8.93M (-7.0%)
|
9.11M
est: 10.72M (-15.1%)
|
9.46M
est: 11.27M (-16.1%)
|
10.39M
est: 11.14M (-6.8%)
|
11.52M
est: 11.42M (+0.8%)
|
13.66M
est: 14.56M (-6.2%)
|
15.28M
est: 14.20M (+7.6%)
|
17.27M
est: 16.63M (+3.8%)
|
17.65M
est: 18.05M (-2.3%)
|
20.46M
est: 22.23M (-8.0%)
|
34.98M
34.98M – 34.98M
+57.3% YoY
|
40.29M
40.29M – 40.29M
+15.2% YoY
|
42.63M
42.63M – 42.63M
+5.8% YoY
|
| EPS |
0.27
est: 0.25 (+8.0%)
|
0.30
est: 0.29 (+5.3%)
|
0.36
est: 0.36 (+0.0%)
|
0.39
est: 0.38 (+1.7%)
|
0.31
est: 0.31 (+0.0%)
|
0.29
est: 0.30 (-3.3%)
|
0.50
est: 0.41 (+22.0%)
|
0.44
est: 0.43 (+2.3%)
|
0.54
est: 0.58 (-6.9%)
|
0.63
est: 0.63 (+0.0%)
|
0.80
est: 0.79 (+1.3%)
|
0.94
0.94 – 0.94
+19.0% YoY
|
1.12
1.12 – 1.12
+19.1% YoY
|
1.25
1.25 – 1.25
+11.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-01 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| René C. Goehrum | Chairman, Chief Executive Officer & President | 621.3K | male |
| Robert J. March | Vice President of Finance & Chief Financial Officer | 341.9K | male |
| Marnie Mccormick | Vice President & GM | 309.5K | female |
| Joost van der Mark | Vice President of Corporate Development | 264.5K | male |
| Kevin Wilson | Vice President of Sales | 216.4K | male |
| Neelu Atwal | Director of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RX.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
